^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    EphA2 receptor antagonist

    Related drugs:
    Apply
    Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia (NCT00792948)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    09/01/2009
    Primary completion :
    06/01/2016
    Completion :
    01/06/2026
    ABL1 • BCR • CD22 • CD5 • CD79A • MME • CD7 • ANPEP • MPO
    |
    dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • sirolimus • leucovorin calcium • Hemady (dexamethasone tablets) • Neupogen (filgrastim) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
    Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations (AALL1131) (NCT02883049)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/21/2025
    Initiation :
    02/29/2012
    Primary completion :
    12/31/2022
    Completion :
    10/03/2025
    ABL1 • BCR • RUNX1 • KMT2A • ETV6
    |
    MLL rearrangement
    |
    dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • methotrexate • vincristine • prednisone • daunorubicin • clofarabine • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine delayed release (DR6MP) • mercaptopurine • thioguanine • Hemady (dexamethasone tablets) • Starasid (cytarabine ocfosfate) • cyclophosphamide intravenous
    Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia. (NCT00390793)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    02/17/2025
    Initiation :
    09/28/2006
    Primary completion :
    02/02/2024
    Completion :
    02/02/2024
    ABL1 • BCR
    |
    dasatinib • cytarabine • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • prednisone • daunorubicin • Starasid (cytarabine ocfosfate)
    Imatinib Mesylate or Dasatinib in Treating Patients With Previously Untreated Chronic Phase Chronic Myelogenous Leukemia (NCT00070499)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    12/27/2024
    Initiation :
    08/15/2004
    Primary completion :
    11/01/2010
    Completion :
    02/22/2025
    ABL1 • BCR
    |
    dasatinib • imatinib
    Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia (NCT00254423)
    Phase 2
    M.D. Anderson Cancer Center
    Active, not recruiting
    Last update posted :
    06/12/2024
    Initiation :
    11/08/2005
    Primary completion :
    11/30/2024
    Completion :
    11/30/2024
    ABL1 • BCR • IFNA1
    |
    dasatinib
    Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel™) (NCT02013648)
    Phase 3
    University of Ulm
    Completed
    Last update posted :
    02/23/2024
    Initiation :
    07/01/2014
    Primary completion :
    02/01/2024
    Completion :
    02/01/2024
    RUNX1 • RUNX1T1
    |
    RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion
    |
    dasatinib • daunorubicin • idarubicin hydrochloride
    Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) (NCT00255346)
    Phase 2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    12/18/2023
    Initiation :
    11/15/2005
    Primary completion :
    03/03/2017
    Completion :
    03/03/2017
    KIT
    |
    KIT positive
    |
    dasatinib
    KISS Study: Kinase Inhibition With Sprycel Start up (NCT03193281)
    Phase 2
    University of Auckland, New Zealand
    Active, not recruiting
    Last update posted :
    11/29/2023
    Initiation :
    07/17/2017
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    ABL1 • BCR
    |
    dasatinib • imatinib
    Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (NCT03625388)
    Phase 2
    Hikma Pharmaceuticals LLC
    Completed
    Last update posted :
    09/22/2023
    Initiation :
    11/05/2018
    Primary completion :
    07/22/2023
    Completion :
    07/22/2023
    ABL1 • BCR
    |
    dasatinib
    A Phase II Study of Dasatinib in Children and Adolescents With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML) or With Ph+ Leukemias Resistant or Intolerant to Imatinib (NCT00777036)
    Phase 2
    Bristol-Myers Squibb
    Active, not recruiting
    Last update posted :
    09/13/2023
    Initiation :
    03/20/2009
    Primary completion :
    09/01/2016
    Completion :
    12/07/2029
    ABL1 • BCR
    |
    dasatinib • imatinib
    Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression (NCT04180371)
    Phase 1/2
    BicycleTx Limited
    Recruiting
    Last update posted :
    07/17/2023
    Initiation :
    11/07/2019
    Primary completion :
    12/31/2023
    Completion :
    12/31/2024
    CD4 • EPHA2
    |
    Opdivo (nivolumab) • BT5528
    Dasatinib in Treating Patients With Locally Advanced or Metastatic Mucosal Melanoma, Acral Melanoma, or Vulvovaginal Melanoma That Cannot Be Removed By Surgery (NCT00700882)
    Phase 2
    Eastern Cooperative Oncology Group
    Completed
    Last update posted :
    06/30/2023
    Initiation :
    07/02/2009
    Primary completion :
    05/06/2016
    Completion :
    12/28/2020
    KIT
    |
    KIT mutation • KIT positive • KIT amplification
    |
    dasatinib
    Study of Dasatinib vs Imatinib in Patients With Chronic Myeloid Leukemia (CML) Who Did Not Have Favorable Response to Imatinib (DASCERN) (NCT01593254)
    Phase 2b
    Bristol-Myers Squibb
    Completed
    Last update posted :
    06/22/2023
    Initiation :
    09/12/2012
    Primary completion :
    11/08/2017
    Completion :
    04/12/2022
    ABL1 • BCR
    |
    dasatinib • imatinib
    Dasatinib Holiday for Improved Tolerability (DasaHIT) (NCT02890784)
    Phase 3
    University of Jena
    Completed
    Last update posted :
    05/10/2023
    Initiation :
    08/01/2016
    Primary completion :
    03/31/2023
    Completion :
    03/31/2023
    ABL1 • BCR
    |
    dasatinib
    Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia (NCT01238211)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    03/01/2023
    Initiation :
    12/14/2010
    Primary completion :
    07/01/2013
    Completion :
    03/15/2021
    RUNX1 • RUNX1T1
    |
    RUNX1-RUNX1T1 fusion • CBFB-MYH11 fusion
    |
    dasatinib • cytarabine • daunorubicin • Starasid (cytarabine ocfosfate)
    Cytochrome P450 Inhibition to Decrease Dosage of Dasatinib for Chronic Myelogenous Leukemia (NCT05638763)
    Phase 2
    Hospital Universitario Dr. Jose E. Gonzalez
    Recruiting
    Last update posted :
    12/06/2022
    Initiation :
    11/01/2024
    Primary completion :
    11/01/2024
    Completion :
    11/01/2024
    ABL1
    |
    dasatinib
    Open-Label Study Evaluating Dasatinib Therapy Discontinuation in Patients With Chronic Phase Chronic Myeloid Leukemia With Stable Complete Molecular Response (DASFREE) (NCT01850004)
    Phase 2
    Bristol-Myers Squibb
    Completed
    Last update posted :
    11/03/2022
    Initiation :
    01/22/2014
    Primary completion :
    09/20/2017
    Completion :
    10/08/2021
    ABL1 • BCR
    |
    dasatinib
    Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP (NCT04155411)
    Phase 4
    Shenzhen Second People's Hospital
    Recruiting
    Last update posted :
    07/27/2022
    Initiation :
    12/01/2019
    Primary completion :
    12/01/2022
    Completion :
    12/01/2023
    ABL1 • BCR
    |
    dasatinib
    Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia (NCT05042531)
    Phase N/A
    LanZhou University
    Recruiting
    Last update posted :
    04/25/2022
    Initiation :
    11/13/2021
    Primary completion :
    09/01/2023
    Completion :
    12/15/2023
    TP53 • CDH1 • CASP3 • DNMT1 • CASP8 • DNMT3B • CDKN1A
    |
    dasatinib • azacitidine
    Dasatinib in Combination With Zoledronic Acid for the Treatment of Breast Cancer With Bone Metastasis (NCT00566618)
    Phase 1/2
    M.D. Anderson Cancer Center
    Completed
    Last update posted :
    02/25/2022
    Initiation :
    11/01/2007
    Primary completion :
    11/17/2020
    Completion :
    11/17/2020
    ER • PGR
    |
    ER positive • PGR positive
    |
    dasatinib • zoledronic acid
    Study of Frontline Dasatinib Plus Chemotherapy in Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PH+ALL) (NCT01724879)
    Phase 2
    Goethe University
    Completed
    Last update posted :
    01/26/2022
    Initiation :
    11/01/2011
    Primary completion :
    09/01/2015
    Completion :
    09/01/2015
    ABL1 • BCR
    |
    dasatinib • cytarabine • cyclophosphamide • vindesine
    Front-line Treatment of BCR-ABL+ Chronic Myeloid Leukemia (CML) With Dasatinib (CML1113) (NCT01761890)
    Phase N/A
    Gruppo Italiano Malattie EMatologiche dell'Adulto
    Active, not recruiting
    Last update posted :
    01/05/2022
    Initiation :
    01/28/2014
    Primary completion :
    12/02/2018
    Completion :
    12/01/2022
    ABL1 • BCR
    |
    dasatinib
    Pediatric Philadelphia Positive Acute Lymphoblastic Leukemia (AALL1122) (NCT01460160)
    Phase 2
    Bristol-Myers Squibb
    Completed
    Last update posted :
    12/08/2021
    Initiation :
    04/13/2012
    Primary completion :
    05/28/2017
    Completion :
    06/01/2021
    ABL1 • BCR
    |
    dasatinib
    A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP) (NCT04925141)
    Phase 4
    Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
    Completed
    Last update posted :
    06/14/2021
    Initiation :
    05/10/2016
    Primary completion :
    10/22/2018
    Completion :
    12/06/2019
    BCR
    |
    dasatinib
    Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia (NCT00306202)
    Phase 1
    Bristol-Myers Squibb
    Completed
    Last update posted :
    02/26/2021
    Initiation :
    03/31/2006
    Primary completion :
    05/31/2011
    Completion :
    05/22/2019
    FLT3 • ABL1 • BCR • KIT
    |
    KIT mutation
    |
    dasatinib
    BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate (NCT00064233)
    Phase 1
    Jonsson Comprehensive Cancer Center
    Completed
    Last update posted :
    08/03/2020
    Initiation :
    11/01/2003
    Primary completion :
    10/01/2006
    Completion :
    10/01/2006
    CD4
    |
    dasatinib • imatinib
    Phase II Trial of Dasatinib in Patients With Isocitrate Dehydrogenase (IDH)-Mutant Advanced Intrahepatic Cholangiocarcinoma (NCT02428855)
    Phase 2
    Massachusetts General Hospital
    Completed
    Last update posted :
    07/31/2020
    Initiation :
    04/01/2015
    Primary completion :
    02/01/2018
    Completion :
    02/01/2018
    IDH1 • IDH2
    |
    IDH2 mutation
    |
    dasatinib
    Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X) (NCT04439305)
    Phase 2
    National Cancer Institute (NCI)
    Withdrawn
    Last update posted :
    07/20/2020
    Initiation :
    02/25/2016
    Primary completion :
    06/07/2018
    DDR2
    |
    DDR2 S768R
    |
    dasatinib
    Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia (AALL0622) (NCT00720109)
    Phase 2/3
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    04/13/2020
    Initiation :
    07/14/2008
    Primary completion :
    12/31/2014
    Completion :
    03/31/2020
    ABL1 • BCR
    |
    dasatinib • cytarabine • cyclophosphamide • ifosfamide • etoposide IV • methotrexate • vincristine • daunorubicin • leucovorin calcium • Oncaspar liquid (pegaspargase) • mercaptopurine • Kidrolase (L-asparaginase) • Leunase (L-asparaginase) • Neupogen (filgrastim) • Spectrila (asparaginase Escherichia coli) • Starasid (cytarabine ocfosfate)
    PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC (NCT04284202)
    Phase 2
    The Affiliated Hospital of Qingdao University
    Unknown status
    Last update posted :
    02/25/2020
    Initiation :
    03/01/2020
    Primary completion :
    12/31/2020
    Completion :
    12/31/2021
    ARID1A
    |
    ARID1A mutation
    |
    dasatinib
    Combination of Dasatinib and Peg-Interferon Alpha 2b in First Line for Chronic Myeloid Leukemia in Chronic Phase (NCT01872442)
    Phase 2
    Poitiers University Hospital
    Completed
    Last update posted :
    02/10/2020
    Initiation :
    10/15/2013
    Primary completion :
    10/31/2018
    Completion :
    10/31/2018
    ABL1 • BCR • IFNA1
    |
    dasatinib
    Treatment-free Remission Accomplished With Dasatinib in Patients With CML (TRAD) (NCT02268370)
    Phase 2
    University Health Network, Toronto
    Unknown status
    Last update posted :
    11/29/2019
    Initiation :
    10/01/2014
    Primary completion :
    10/01/2020
    Completion :
    10/01/2021
    ABL1 • BCR
    |
    dasatinib
    Assess Long-term Feasibility of Reduced Dose Dasatinib in Chronic Phase Chronic Myeloid Leukemia Patients (NCT04150471)
    Phase N/A
    Seoul St. Mary's Hospital
    Recruiting
    Last update posted :
    11/04/2019
    Initiation :
    10/18/2018
    Primary completion :
    12/30/2020
    Completion :
    12/30/2023
    ABL1 • BCR
    |
    dasatinib
    Dendritic Cell Vaccines + Dasatinib for Metastatic Melanoma (NCT01876212)
    Phase 2
    Walter J. Storkus
    Completed
    Last update posted :
    08/22/2019
    Initiation :
    05/16/2014
    Primary completion :
    07/11/2018
    Completion :
    07/31/2019
    CD8 • CXCL10
    |
    M-MDSCs
    |
    dasatinib
    Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194 (NCT00820170)
    Phase 1/2
    Memorial Sloan Kettering Cancer Center
    Completed
    Last update posted :
    08/13/2019
    Initiation :
    01/01/2009
    Primary completion :
    08/01/2018
    Completion :
    08/01/2018
    HER-2 • PGR • KDR
    |
    HER-2 negative
    |
    dasatinib • paclitaxel
    Treating Patients With Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) With Dasatinib (DasPAQT) (NCT02348957)
    Phase N/A
    Onco Medical Consult GmbH
    Completed
    Last update posted :
    07/25/2019
    Initiation :
    10/01/2014
    Primary completion :
    03/01/2019
    Completion :
    05/01/2019
    ABL1 • BCR
    |
    dasatinib
    Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma (NCT00423735)
    Phase 2
    National Cancer Institute (NCI)
    Completed
    Last update posted :
    07/24/2019
    Initiation :
    01/24/2007
    Primary completion :
    03/09/2011
    Completion :
    09/04/2018
    KIT • SRC
    |
    dasatinib
    A Study Using Two Oral Chemotherapy Agents for Chronic Lymphocytic Leukemia (NCT00829647)
    Phase 1/2
    Scripps Health
    Withdrawn
    Last update posted :
    04/11/2019
    Initiation :
    01/01/2009
    Primary completion :
    12/01/2009
    Completion :
    03/01/2016
    CD38
    |
    Chr del(11q)
    |
    dasatinib • lenalidomide • Campath (alemtuzumab)